<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Infectious and Tropical Diseases</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ED2375AB-9E15-4A39-90CE-7EBAC0C8FF9B"><gtr:id>ED2375AB-9E15-4A39-90CE-7EBAC0C8FF9B</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:surname>Grant</gtr:surname><gtr:orcidId>0000-0002-2437-5195</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8382C86-88A9-4916-8A3C-9CE2BA5170C8"><gtr:id>B8382C86-88A9-4916-8A3C-9CE2BA5170C8</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Churchyard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D8DE61AC-E470-46C7-9592-8FD8D0C21A67"><gtr:id>D8DE61AC-E470-46C7-9592-8FD8D0C21A67</gtr:id><gtr:firstName>Katherine</gtr:firstName><gtr:surname>Fielding</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/59DFD9FD-B5D8-4BE8-BC60-CFB8A421B2A1"><gtr:id>59DFD9FD-B5D8-4BE8-BC60-CFB8A421B2A1</gtr:id><gtr:firstName>Salome</gtr:firstName><gtr:surname>Charalambous</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DE9CE68F-002D-400D-A2B0-6F43342D1BD8"><gtr:id>DE9CE68F-002D-400D-A2B0-6F43342D1BD8</gtr:id><gtr:firstName>Suzanne</gtr:firstName><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9B33144F-0BA1-43CE-8469-4F3AC76D6839"><gtr:id>9B33144F-0BA1-43CE-8469-4F3AC76D6839</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Hoffmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6889170F-FA31-4384-B967-D1D9FA700925"><gtr:id>6889170F-FA31-4384-B967-D1D9FA700925</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:surname>Dorman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1874C8EB-D19F-4981-87A3-04FCE301FBB3"><gtr:id>1874C8EB-D19F-4981-87A3-04FCE301FBB3</gtr:id><gtr:firstName>Kerrigan</gtr:firstName><gtr:surname>McCarthy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/50FEA296-9995-47B2-B25B-DC5A985D6085"><gtr:id>50FEA296-9995-47B2-B25B-DC5A985D6085</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:surname>Vassall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100689"><gtr:id>1CE93E73-1C54-4073-9254-585B69ACB416</gtr:id><gtr:title>TB fast track: effect of a point-of-care TB test-and-treat algorithm on early mortality in people with HIV accessing ART</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100689</gtr:grantReference><gtr:abstractText>Treatment for HIV (antiretroviral therapy, or ART), has greatly reduced death rates among people with HIV worldwide. However in low-resource settings, death rates continue to be high even for people taking ART, particularly in the first few months on treatment. Tuberculosis (TB) is the most important cause of these early deaths, and people who are due to start ART are recommended to be screened for TB first. However, TB is hard to diagnose because the tests which are most widely available do not work well for people with HIV. As a result, people with HIV may have to go through lots of tests for TB, which delays the start of TB treatment; it also delays the start of ART. Both of these delays increase the risk that the patient dies. 
We propose a study to try to reduce this high death rate. In 20 primary care clinics in South Africa, we will enrol people with advanced HIV who have come to start ART to our study. In 10 of the clinics (intervention), selected at random, we will use simple, inexpensive tests (a new urine test for TB, weight and height, and a blood test for anaemia) which can be done on site with immediate results, to identify those patients who are at highest risk of having TB, and of dying early. People who are high risk will start TB treatment straight away, then ART as soon as possible afterwards; people who are low TB risk will start ART straight away. People with medium TB risk will be given antibiotics while a chest X-ray and sputum (spit) test for TB are done, and will come back after a week to decide if they should start TB treatment followed by ART, or just start ART. At the other 10 (control) clinics, patients will be looked after in the normal way, following national guidelines. We will follow all patients up for 6 months. We will compare the death rate at 6 months in the 10 intervention clinics, using our new approach, to death rates in the 10 control clinics, using the routine approach. If our new approach reduces the death rate, clinics throughout low resource settings could use this low-cost strategy to save lives among people with HIV.</gtr:abstractText><gtr:technicalSummary>Background: Early mortality remains high among adults with HIV accessing antiretroviral therapy (ART) in resource-constrained settings, with tuberculosis (TB) a leading cause of death. 20% people accessing ART in South Africa have undiagnosed TB. However, due to insensitivity of sputum microscopy, and a complex diagnostic pathway for smear-negative TB, the time to TB diagnosis is protracted, delaying both TB treatment (among those diagnosed with TB) and ART (among all investigated, whether or not TB is diagnosed). We hypothesise that a care pathway using point-of-care technology to rapidly identify individuals presenting for ART at high risk of TB and ensure they start TB treatment, then ART, will markedly reduce early mortality.
Objective: To compare 6-month mortality among patients with HIV disease and CD4 150 cells/?l referred to start ART between intervention clinics implementing a point-of-care algorithm to identify individuals with a high probability of active TB, and facilitate rapid initiation of TB treatment, followed by ART; vs. control clinics delivering standard of care management according to South African TB/HIV care guidelines.
Methods: This is a cluster-randomised trial, randomising 20 primary health clinics in Gauteng and Limpopo provinces, South Africa. ART-eligible patients (CD4 150, ambulant, no recent TB treatment) at intervention clinics will be assessed using simple point-of-care assays. Patients with any of: positive urine lipoarabinomannan (LAM), haemoglobin (Hb) 10, body mass index (BMI) 18.5 will be considered high probability TB, and start TB treatment immediately, then ART. Asymptomatic patients with negative LAM, Hb 10, BMI 18.5 will be low probability and will start ART. Others ( medium probability ) will be investigated for smear-negative TB as per South African guidelines with review after one week to re-categorise into high or low probability. In control clinics we will recruit similar patients and obtain permission for follow-up; management will be as per national guidelines. The primary outcome is mortality at 6 months after recruitment; secondary outcomes include severe morbidity, measured by duration of hospitalisation. Diagnostic cost per TB case detected, and cost per DALY, will be estimated. We estimate mortality conservatively at 25/100 person years in the control arm; with 10 clusters per arm, 175 patients per cluster, and 95% ascertainment of vital status at 6 months, using between-cluster coefficients of variation of 0.2 and 0.25, there will be 91% and 85% power to assess 40% reduction in mortality, respectively. 
Significance: This strategy may result in a major reduction in mortality for people with HIV.</gtr:technicalSummary><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3202542</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference presentation (Blizard)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F656902E-7B16-4FE8-8B63-D8E5092CBDFA</gtr:id><gtr:impact>Talk stimulated a number of interesting questions from a range of participants

Several audience members wanted to discuss the study strategy after the talk.</gtr:impact><gtr:outcomeId>54629379e98c49.33688796</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV interview (Durban)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4127F20C-5E19-42B0-AFC4-CB0396EB5126</gtr:id><gtr:impact>Alison Grant interviewed by TV team for Africa News Network 7 about TB in South Africa and its importance as a cause of death.</gtr:impact><gtr:outcomeId>58c492746a0ad6.92991006</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Empirical TB treatment symposium (Union TB conference)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DACF8FCD-17DB-4ACB-8DCA-4A69900349F5</gtr:id><gtr:impact>Symposium at the Union TB meeting in which lead researchers of all current and recent trials of empirical TB treatment presented their studies. Talk was followed by a lively discussion about trials of empirical TB treatment

Following from this talk, I have been asked by WHO TB department to take part in a symposium on empirical TB treatment at the US HIV conference 2015. In addition, we are in discussion with WHO TB department about how the results of this trial may feed into WHO guidelines.</gtr:impact><gtr:outcomeId>5462974a327785.71577834</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International AIDS conference: TB Fast Track symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>56045F7F-C998-46A2-9F5B-FFD4EDDE1D5A</gtr:id><gtr:impact>Presentation of TB Fast Track results in a symposium on TB diagnosis among people with HIV. Attended by policy makers from WHO, Stop TB, UNAIDS, South African department of health, funders, implementers, researchers. Following from the presentation, Alison Grant was interviewed by a South African television news channel, and was invited to join a WHO guideline group.</gtr:impact><gtr:outcomeId>58c491c6cd7187.46978566</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://programme.aids2016.org/Programme/Session/955</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Union conference: WHO symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5CBA539-E85A-4D31-A72B-5F3C781E0EA5</gtr:id><gtr:impact>Presentation of TB Fast Track results at WHO-organised symposium &amp;quot;Enough is enough - Time to end preventable mortality among people living with HIV!&amp;quot;</gtr:impact><gtr:outcomeId>58c494653f6382.78334071</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://liverpool.worldlunghealth.org/programme/symposia</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Global Health Lecture Series (LSHTM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C7E73DB1-35F2-4245-94BA-5472C7D6EEAB</gtr:id><gtr:impact>Students were keen to ask questions about the intervention strategy

Several students contacted me after the talk to find out more and to ask if they could contribute to the project. Two students subsequently undertook MSc projects within the larger project.</gtr:impact><gtr:outcomeId>5462955adb8a24.84648396</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International AIDS conference: CDC symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5F0F39B0-97E9-42B5-9C9E-8E9AE8727005</gtr:id><gtr:impact>Presentation of TB Fast Track results at a CDC symposium: A Survival Guide for Advanced HIV Disease: Increasing Access to and Knowledge of Life-Saving Interventions.</gtr:impact><gtr:outcomeId>58c48ff7c66a86.02059320</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://programme.aids2016.org/Programme/Session/1048</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at HIV academic meeting (St Mary's)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>86C387B1-72EC-473E-A4CC-70BBA6A6F393</gtr:id><gtr:impact>Talk was followed by lively discussion of study strategy.

After my talk other researchers were interested to share experience around patient engagement in HIV care</gtr:impact><gtr:outcomeId>546294653302f3.27639803</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Department of health briefing, Cape Town</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>08B84655-8121-402A-9B85-406ACAAFFF48</gtr:id><gtr:impact>We met with Dr Yogan Pillay, Deputy Director - General: HIV/AIDS, TB and Maternal, Child and Womens Health in the National Department of Health, South Africa, in order to give him a private briefing of the results of the TB Fast Track trial, since the trial results are of direct relevance to his department.</gtr:impact><gtr:outcomeId>56d9a0a46796b6.44988172</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HIV research meeting, Mortimer Market</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CC7A0545-ECB6-4080-9955-D5527576D32F</gtr:id><gtr:impact>Presentation of the trial at the HIV research meeting, Mortimer Market centre. Increased knowledge of TB and empirical TB treatment</gtr:impact><gtr:outcomeId>56da945cf2f422.20260196</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference presentation (SATB 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C006E423-AAA8-4DC1-9C37-E297D9AB9D3D</gtr:id><gtr:impact>Talk resulted in several questions about the study

The talk has helped to raise awareness of the study among the South African TB community</gtr:impact><gtr:outcomeId>54629854c8efe2.14291669</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.tbconference.co.za/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Feedback on TB Fast Track</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D6DA4CBA-3DC9-4FA8-8113-875C4C5FBF62</gtr:id><gtr:impact>Feedback of study results to Sekhukhkune Department of Health, South Africa. Discussion focussed on how best to diagnose TB among HIV+ patients.</gtr:impact><gtr:outcomeId>58c48c26e96d28.08298136</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CROI 2016 press briefing</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8315F24C-7E0B-4C0C-87D8-26180AEA29B0</gtr:id><gtr:impact>I gave a press briefing concerning my CROI 2016 conference presentation, discussing the primary outcome of the study, to invited journalists. This led to several press items being published.</gtr:impact><gtr:outcomeId>56da8f6b1d4ce4.69378487</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Feedback on TB Fast Track</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AFB0D56F-2932-4258-B30D-D7ADB7B0D6D4</gtr:id><gtr:impact>Discussion of study results with Limpopo provincial ethics committee, South Africa. Study team was requested to provide further feedback to clinicians in the study area.</gtr:impact><gtr:outcomeId>58c4890ae935d0.52862766</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meeting for clinics and district TB/HIV coordinators</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DFFAE855-2EE6-4E2C-923B-4A68F1776626</gtr:id><gtr:impact>Around 50 clinic staff and district / regional HIV/TB coordinators attended a progress update meeting with questions afterwards.

Increased interest in and understanding of the study. Clinic staff were interested to know how they could promote participation in the study at their clinic.</gtr:impact><gtr:outcomeId>VY6ayLsH3Pn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TB Fast Track results presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1FF4D0D8-EE34-47D0-91E8-C8FD6CBE27FA</gtr:id><gtr:impact>Presentation of TB Fast Track study results to Southern African HIV clinicians society meeting. Discussion focussed on importance of prompt ART initiation and importance of mixed infections as cause of death amongst these patients.</gtr:impact><gtr:outcomeId>58c48cea341218.94642574</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Feedback on TB Fast Track</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>89101F75-C812-4E77-99AD-5001888E0979</gtr:id><gtr:impact>Presentation of study results to Tshwane Department of Health, South Africa. Discussion focussed on need to initiate antiretroviral therapy promptly.</gtr:impact><gtr:outcomeId>58c48b1b4c9727.23896246</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>599127</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Prevalence of TB at autopsy in South Africa</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1083118</gtr:fundingRef><gtr:id>7CC387AE-28F9-42DB-98A3-8E1B7278B071</gtr:id><gtr:outcomeId>szs8qEhGCgM</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Young investigator award</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Conference on Retroviruses and Opportunistic Infections (CROI)</gtr:fundingOrg><gtr:id>8AEB30A4-A496-4F9A-9AEA-E37F81C04093</gtr:id><gtr:outcomeId>58c482c38106a3.32108879</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in WHO LF-LAM guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV</gtr:guidelineTitle><gtr:id>F8FFD596-D451-48FA-9B71-3B468C2B4378</gtr:id><gtr:outcomeId>56ddf9bdc79767.94311332</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.who.int/tb/publications/use-of-lf-lam-tb-hiv/en/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The intervention is a management strategy for people with HIV and CD4&amp;lt;150, in primary care clinics in South Africa, who are not currently taking ART or TB treatment. The intervention uses point of care tests (urine LAM, haemoglobin and BMI) to assign probability of TB. Patients assigned high probability start TB treatment immediately followed by ART after two weeks. The aim is to reduce mortality as measured after 6 months.
The strategy is currently being tested in a cluster-randomised trial funded by Global Health Trials.</gtr:description><gtr:id>3785F03F-4E56-4A2D-B2BA-AA0EA63C01EB</gtr:id><gtr:impact>Trial is in progress</gtr:impact><gtr:outcomeId>NUzG6qGD8TT</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>TB Fast Track</gtr:title><gtr:type>Health and Social Care Services</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN35344604</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Autopsy data from TB Fast Track research participants</gtr:description><gtr:id>218B2759-F033-49CD-9DC1-79F7701C8615</gtr:id><gtr:impact>not yet known</gtr:impact><gtr:outcomeId>58c49a89baf5a7.60827682</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TB Fast Track autopsy data</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://datacompass.lshtm.ac.uk/243/</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>39E0B82A-DA59-4BD1-B146-1B3E90524E64</gtr:id><gtr:title>Autopsy prevalence of TB and other infections in adults with advanced HIV enrolled in out-patient care in South Africa.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/587f125912f781370d397bcd9437ebfa"><gtr:id>587f125912f781370d397bcd9437ebfa</gtr:id><gtr:otherNames>Karat A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c4854cbcf9b7.75012948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03307CBA-DE52-43F6-86FE-55ABD90A7CED</gtr:id><gtr:title>Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0023127998e14aeaba4cc21733a2a9a"><gtr:id>d0023127998e14aeaba4cc21733a2a9a</gtr:id><gtr:otherNames>Karat AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aa461ba934c86.48812687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85D0CF44-12F3-41D5-8ED6-E2DF961BBE98</gtr:id><gtr:title>Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV Enrolled in Out-Patient Care in South Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0023127998e14aeaba4cc21733a2a9a"><gtr:id>d0023127998e14aeaba4cc21733a2a9a</gtr:id><gtr:otherNames>Karat AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c47f7f4ed264.23376215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5759BB8B-A67F-408E-8BE0-D1F19DEE290A</gtr:id><gtr:title>Sensitivity of the TB Determine LAM test compared to sputum culture gold standard TB in ambulant HIV positive participants enrolled in the TB fast track study in South Africa</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/297c29e6e9b0e107939992ad895a58ee"><gtr:id>297c29e6e9b0e107939992ad895a58ee</gtr:id><gtr:otherNames>Tlali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56dd9fd353afc8.93995753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB4F9DE3-BDF4-4C19-95F1-30EB7A7075CA</gtr:id><gtr:title>CROI 2016 presentation</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85a60e5066ab5ec74048e84f9e035c69"><gtr:id>85a60e5066ab5ec74048e84f9e035c69</gtr:id><gtr:otherNames>Grant AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56d9fc469faf79.40156496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B14E7B4-D666-4CEF-9486-950B243854EC</gtr:id><gtr:title>Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b44432725e63dd5e30d32cb3c3365d3"><gtr:id>4b44432725e63dd5e30d32cb3c3365d3</gtr:id><gtr:otherNames>Fielding KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5675e25f97fe4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D68890F-CAE9-473F-A0E3-41AA47CA855E</gtr:id><gtr:title>The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9640e5ec0a493562ad2a4bee17ef9cc7"><gtr:id>9640e5ec0a493562ad2a4bee17ef9cc7</gtr:id><gtr:otherNames>Odone A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675dcc074ee6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0E91AA3-280A-404F-94A6-FEDFE8C9BC01</gtr:id><gtr:title>Tuberculosis investigations for HIV-positive people prior to ART initiation: routine practice in primary care clinics in South Africa</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7e302da9c874017f93d8053e4040ef1"><gtr:id>f7e302da9c874017f93d8053e4040ef1</gtr:id><gtr:otherNames>Minja N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56da91737d2d07.32450201</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100689</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>